04:39 PM EDT, 06/30/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Monday it started a phase 1 trial to assess investigational drug NBIP-01435 in healthy adult participants to potentially treat congenital adrenal hyperplasia.

The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of NBIP-01435, the company said.

Congenital adrenal hyperplasia is a rare genetic condition that results in an enzyme deficiency that alters adrenal steroid hormones production.